- Home
- VNDA vs DBI Comparison
VNDA vs DBI Comparison
Compare VNDA & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- DBI
- Stock Information
- Founded
- VNDA 2002
- DBI 1991
- Country
- VNDA United States
- DBI United States
- Employees
- VNDA N/A
- DBI N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- DBI Clothing/Shoe/Accessory Stores
- Sector
- VNDA Health Care
- DBI Consumer Discretionary
- Exchange
- VNDA Nasdaq
- DBI Nasdaq
- Market Cap
- VNDA 257.8M
- DBI 250.2M
- IPO Year
- VNDA 2006
- DBI 1991
- Fundamental
- Price
- VNDA $4.43
- DBI $4.78
- Analyst Decision
- VNDA Strong Buy
- DBI Hold
- Analyst Count
- VNDA 2
- DBI 2
- Target Price
- VNDA $16.50
- DBI $5.75
- AVG Volume (30 Days)
- VNDA 640.7K
- DBI 1.7M
- Earning Date
- VNDA 02-13-2025
- DBI 03-20-2025
- Dividend Yield
- VNDA N/A
- DBI 4.12%
- EPS Growth
- VNDA N/A
- DBI N/A
- EPS
- VNDA N/A
- DBI N/A
- Revenue
- VNDA $198,772,000.00
- DBI $3,050,038,000.00
- Revenue This Year
- VNDA $16.07
- DBI N/A
- Revenue Next Year
- VNDA $24.42
- DBI $2.16
- P/E Ratio
- VNDA N/A
- DBI N/A
- Revenue Growth
- VNDA 3.18
- DBI N/A
- 52 Week Low
- VNDA $3.71
- DBI $4.36
- 52 Week High
- VNDA $6.75
- DBI $11.57
- Technical
- Relative Strength Index (RSI)
- VNDA 44.53
- DBI 39.62
- Support Level
- VNDA $4.34
- DBI $5.05
- Resistance Level
- VNDA $4.65
- DBI $5.30
- Average True Range (ATR)
- VNDA 0.21
- DBI 0.27
- MACD
- VNDA -0.01
- DBI -0.02
- Stochastic Oscillator
- VNDA 36.51
- DBI 16.90
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.